Alnylam Pharmaceuticals Inc (MEX:ALNY)
MXN 5899.69 0 (0%) Market Cap: 699.59 Bil Enterprise Value: 669.88 Bil PE Ratio: 0 PB Ratio: 1,075.42 GF Score: 78/100

Alnylam Pharmaceuticals Inc at UBS Global Healthcare Virtual Conference Transcript

May 25, 2021 / 07:00PM GMT
Release Date Price: MXN2670
Navin Cyriac Jacob
UBS Investment Bank, Research Division - Equity Research Analyst of Specialty Pharmaceuticals and Large Cap Pharmaceutic

Good afternoon, again. My name is Navin Jacob. I cover SMID cap biotech and large-cap pharma here at UBS. I'm happy to be here today with Alnylam Pharmaceuticals. And with -- and from Alnylam, I'm excited to have with us President and COO, Yvonne Greenstreet. Yvonne nice to have you here today.

Yvonne L. Greenstreet
Alnylam Pharmaceuticals, Inc. - President & COO

Thanks, Navin. I'm really happy to be here as well. I mean just a few brief introductory remarks with respect to Alnylam. Many of you may know our story, but just to emphasize that we are the leader in RNAi therapeutics. We've been successful in bringing 4 RNAi medicines to market. And this is 3 that we are directly commercializing ourselves, ONPATTRO for hATTR amyloidosis patients with polyneuropathy, GIVLAARI for patients with acute hepatic porphyria and OXLUMO for the patients with primary hyperoxaluria type 1. And then one that's been commercialized by

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot